Aurora Kinase B (Ec 2.7.11.1) Market Share, Size, Treatment, Symptoms, Causes, Pipeline Review, H1 2016

Submitted by: Submitted by

Views: 10

Words: 1065

Pages: 5

Category: Business and Industry

Date Submitted: 11/09/2016 10:07 PM

Report This Essay

Aurora Kinase B (EC 2.7.11.1) Market Size, Treatment,

Symptoms, Causes, Pipeline Review, H1 2016: Radiant Insights

Summary

Global Markets Direct's, 'Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or

Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on

Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein

Kinase 12 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like

Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) , targeted therapeutics,

complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration

(RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its

complete research and development history and latest news and press releases. Additionally, the report provides

an overview of key players involved in Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated

Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics development and features

dormant and discontinued projects.

Browse Ongoing Reports @ http://www.radiantinsights.com/research/aurora-kinase-b-aurora-1

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and

nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's

proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor

presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that

all...